Go Pro
→ Elon Is Quietly Doubling Down on This Bizarre Asset (From Brownstone Research) (Ad)tc pixel Free PXMD Stock Alerts

PaxMedica (PXMD) Competitors

PaxMedica logo
$0.0007 0.00 (0.00%)
As of 07/14/2026
Compare

PXMD vs. SCPS, CLVR, VRPX, TRVN, and NAVB

Should you buy PaxMedica stock or one of its competitors? MarketBeat compares PaxMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PaxMedica include Scopus BioPharma (SCPS), Clever Leaves (CLVR), Virpax Pharmaceuticals (VRPX), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does PaxMedica compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Scopus BioPharma has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

Scopus BioPharma's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

4.9% of PaxMedica shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
PaxMedica Neutral

Summary

Scopus BioPharma beats PaxMedica on 5 of the 6 factors compared between the two stocks.

How does PaxMedica compare to Clever Leaves?

PaxMedica (NASDAQ:PXMD) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Clever Leaves has higher revenue and earnings than PaxMedica. Clever Leaves is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Clever Leaves Neutral

PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market.

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Clever Leaves N/A N/A N/A

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Clever Leaves beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
PaxMedica N/A -3,167.89%-560.35%

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
PaxMedica Neutral

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Virpax Pharmaceuticals has a beta of -16.52, meaning that its share price is 1,752% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Summary

Virpax Pharmaceuticals beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Trevena?

Trevena (NASDAQ:TRVN) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Trevena has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

In the previous week, Trevena had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Trevena and 0 mentions for PaxMedica. Trevena's average media sentiment score of 0.75 beat PaxMedica's score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Positive
PaxMedica Neutral

13.6% of Trevena shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PaxMedica has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Trevena's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
PaxMedica N/A -3,167.89%-560.35%

Summary

Trevena beats PaxMedica on 8 of the 11 factors compared between the two stocks.

How does PaxMedica compare to Navidea Biopharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Navidea Biopharmaceuticals Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PXMD vs. The Competition

Export
MetricPaxMedicaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8K$940.11M$6.78B$12.56B
Dividend YieldN/A4.84%2.68%9.45%
P/E Ratio0.001.5627.0824.35
Price / SalesN/A114.57487.2376.01
Price / CashN/A20.0648.6360.00
Price / Book0.008.5810.826.31
Net Income-$18.29M-$3.40M$3.59B$331.55M
7 Day PerformanceN/A-2.59%-1.80%-0.71%
1 Month PerformanceN/A-0.49%3.71%0.16%
1 Year PerformanceN/A35.38%27.41%19.66%

PaxMedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$8KN/AN/A2
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$21KN/AN/A9
CLVR
Clever Leaves
N/A$0.01
flat		N/AN/A$18K$17.42MN/A560
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/A-96.9%$14KN/AN/A7
TRVN
Trevena
N/A$0.01
flat		N/A-98.8%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
URGENT Dollar Reset Warning for Monday
A 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...
Golden Portfolio | Sponsoredtc pixel
What will Nvidia do next?
Wall Street spends millions on supercomputers and analyst teams to forecast stock prices. Now a new predictive...
TradeSmith | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
BlackRock just moved $150 billion into this "new internet"
BlackRock CEO Larry Fink's 2026 chairman's letter compared tokenization to the birth of the internet - and the...
Awesomely, LLC | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Jeff Brown and Marc Chaikin's latest AI prediction explained
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel